Indomethacin inhibition of intralipid-induced lung dysfunction.
Intralipid-related pulmonary alterations have been attributed to hyperlipemia. To better quantitate and explain these alterations, Intralipid (0.4 gm/kg over one hour) was infused into three groups of rabbits and saline into a fourth group. Group I had normal lung function; Groups II-IV were pretreated with oleic acid and Group III also received indomethacin. Serum triglyceride (TG) levels, arterial (a) and end-tidal (A) PCO2 and PO2 were measured at baseline and then hourly for six hours. There was no ventilatory deterioration in Group I despite a peak TG level of 638 mg/dl. In Group II there was an Intralipid-related PaO2 decrease of 11-13 mmHg (p less than .01) and a delta AaPO2 increase of 16 mmHg (p less than .01); both returned to baseline without significant TG normalization. Since indomethacin prevented these PaO2 and delta AaPO2 changes despite a significant TG increase, the effects of Intralipid appear not to be TG-related but rather to be related to PG-mediated alterations in pulmonary vasomotor tone. Our results are most consistent with a net increase in vasodilating prostaglandins and resultant hypoxemia secondary to unblocking of baseline hypoxic vasoconstriction.
D000818:Animals; D002245:Carbon Dioxide / Q000097:blood; D007213:Indomethacin / Q000494:pharmacology*; D008055:Lipids / Q000009:adverse effects; D008168:Lung / Q000503:physiopathology*; D010100:Oxygen / Q000097:blood; D011453:Prostaglandins / Q000502:physiology; D011654:Pulmonary Edema / Q000097:blood / Q000503:physiopathology*; D011817:Rabbits; D012119:Respiration / Q000187:drug effects*; D013025:Glycine max; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D011453:Prostaglandins; D014280:Triglycerides; D002245:Carbon Dioxide; D010100:Oxygen; D007213:Indomethacin